Streetbeat News

DNA

Ginkgo Bioworks Holdings, Inc.

https://www.ginkgobioworks.com

Industry

Biotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Open

8.30

Mkt cap

472M

Volume

498K

High

8.56

P/E Ratio

-0.47

52-wk high

75.20

Low

8.13

Div yield

N/A

52-wk low

5.26

Ginkgo Bioworks' stock is trading lower following the company's announcement that its preliminary unaudited Cell Engineering revenue for 2023 is expected to be within the previously disclosed guidance range of $145 – $150 million.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 8:24 pm

Ginkgo Bioworks Holdings Inc (NYSE:DNA) reported preliminary FY23 sales of $250-$260 million, aligning with consensus estimates. The company expects cell engineering and biosecurity revenue to be within guidance ranges and anticipates adding 80-85 new Cell Programs in 2023. William Blair views Ginkgo's update positively, despite a reduced full-year program target. Ginkgo completed collaborations with Novo Nordisk (NYSE:NVO) and Biogen Inc (NASDAQ:BIIB), and its cell engineering revenue from biopharma clients grew over 50% in 2023. The company ended the year with $950 million in cash and equivalents. However, concerns about growth feasibility and financial robustness persist, leading William Blair to maintain a Market Perform rating. DNA shares dropped 5.30% to $1.43.

Portfolio Pulse from Vandana Singh

January 10, 2024 | 7:29 pm

Ginkgo Bioworks has successfully completed a collaboration with Biogen, aimed at enhancing the productivity of Biogen's gene therapy manufacturing platform. This collaboration could potentially lead to more efficient production processes for gene therapies.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:11 pm

OneOne Biosciences has entered into a partnership with Ginkgo Bioworks to further develop its platform and advance its nitrogen fixation microbial product. This collaboration aims to enhance OneOne Biosciences' capabilities in creating sustainable agricultural solutions.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 12:08 pm

Ginkgo Bioworks' stock is up following three positive announcements: a Ginkgo-led team received funding from the U.S. Department of Energy (DOE) for algal crop protection solutions, Greenlab formed a new partnership with Ginkgo for PFAS-related work, and Ginkgo's subsidiary FGen AG secured funding through the European Innovation Council's (EIC) Pathfinder Challenge program.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 5:10 pm

FGen AG, a subsidiary of Ginkgo Bioworks, has been awarded funding by the European Innovation Council's Pathfinder Programme to develop a sustainable method for producing milk protein. The project aims to create an alternative to traditional milk production by engineering bacteria to convert CO2 and electricity into whey protein, which could significantly impact the sustainable bioproduction of food, medicine, and chemicals.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 12:10 pm

Ginkgo Bioworks has been awarded funding by the U.S. Department of Energy to develop algal crop protection solutions. This initiative is part of a broader effort to enhance agricultural sustainability and productivity through innovative biotechnology.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 12:09 pm

Ginkgo Bioworks has been awarded a grant to create a live cell platform for delivering antibody therapeutics aimed at treating HIV and malaria. This development could potentially lead to innovative treatments for these diseases.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 12:04 pm

Arbor Biotechnologies has entered into a collaboration with Ginkgo Bioworks to enhance the discovery and development of precision gene editors. This partnership aims to leverage Arbor's expertise in gene editing and Ginkgo's platform for cell programming to advance the field of gene editing.

Portfolio Pulse from Benzinga Newsdesk

December 12, 2023 | 12:06 pm

Brazil's Agrivalle has formed a partnership with Ginkgo Bioworks to develop advanced agricultural biological products, such as next-generation fertilizers and biocontrol agents. The financial terms of the partnership have not been disclosed.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 12:04 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.